134636-34-3 Usage
Structure
Benzene ring with two hydroxyl groups (benzenediol)
Nitro group attached to a pyridine ring
Imidazole moiety connected to the pyridine ring
Pharmacological activity
Potential applications in medicinal chemistry and drug development
Therapeutic purposes
May have applications in the research and development of novel drugs for various therapeutic purposes
Unique structural features
Combination of benzene, pyridine, and imidazole rings with hydroxyl and nitro groups
Biological properties
Potential biological properties that warrant further research
Field of study
Pharmaceutical and biotechnology research
Further research
Studies and research needed to explore the full potential and applications of the compound in the field of pharmaceuticals and biotechnology
Check Digit Verification of cas no
The CAS Registry Mumber 134636-34-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,4,6,3 and 6 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 134636-34:
(8*1)+(7*3)+(6*4)+(5*6)+(4*3)+(3*6)+(2*3)+(1*4)=123
123 % 10 = 3
So 134636-34-3 is a valid CAS Registry Number.
134636-34-3Relevant academic research and scientific papers
Catechol derivatives
-
, (2008/06/13)
Catechol derivatives of the formula STR1 wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adensoylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuornal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure. Formula Ia above embraces not only compounds which form part of the invention, but also known compounds; the compounds which form part of the invention can be prepared according to known methods.
